{"protocolSection": {"identificationModule": {"nctId": "NCT01156844", "orgStudyIdInfo": {"id": "CQAB149B2223"}, "secondaryIdInfos": [{"id": "2010-018481-22", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol", "officialTitle": "A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Repeated-dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Three Different Dosing Regimens of Inhaled Indacaterol Maleate in Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2011-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-03"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-06-30", "studyFirstSubmitQcDate": "2010-07-02", "studyFirstPostDateStruct": {"date": "2010-07-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-07-22", "resultsFirstSubmitQcDate": "2011-07-22", "resultsFirstPostDateStruct": {"date": "2011-08-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-07-22", "lastUpdatePostDateStruct": {"date": "2011-08-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study assessed the bronchodilator efficacy of three different regimens of indacaterol in patients with asthma"}, "conditionsModule": {"conditions": ["Persistent Asthma"], "keywords": ["Indacaterol", "Asthma", "Bronchodilation", "Beta-agonist"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 191, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Indacaterol 37.5 \u00b5g (twice a day)", "type": "EXPERIMENTAL", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.\n\nAll patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol"]}, {"label": "Indacaterol 75 \u00b5g (once a day)", "type": "EXPERIMENTAL", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.\n\nAll patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo to Indacaterol"]}, {"label": "Indacaterol 150 \u00b5g (every other day)", "type": "EXPERIMENTAL", "description": "Indacaterol 150 \u00b5g every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 \u00b5g inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.\n\nAll patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Indacaterol", "Drug: Placebo to Indacaterol"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.\n\nAll patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "interventionNames": ["Drug: Placebo to Indacaterol"]}], "interventions": [{"type": "DRUG", "name": "Indacaterol", "description": "Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.", "armGroupLabels": ["Indacaterol 150 \u00b5g (every other day)", "Indacaterol 37.5 \u00b5g (twice a day)", "Indacaterol 75 \u00b5g (once a day)"]}, {"type": "DRUG", "name": "Placebo to Indacaterol", "description": "Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.", "armGroupLabels": ["Indacaterol 150 \u00b5g (every other day)", "Indacaterol 75 \u00b5g (once a day)", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Trough FEV1 values were calculated as the mean of the 23.17 hours and 23.75 hours post morning dose FEV1 measurements. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "timeFrame": "Baseline to week 2"}, {"measure": "Change From Baseline in the Forced Expiratory Volume in 1 Second Standardized (With Respect to Time) Area Under the Curve (AUC) From 0 to 24 Hours Post Dose (FEV1 AUC 0-24h) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC 0-24 hours) of FEV1 measurements taken at pre-dose to 24 hours post-dose was calculated based on the trapezoidal rule and was adjusted for the area per time unit using the scheduled time of measurements for FEV1. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "timeFrame": "Baseline, 0-24 hours post dose week 2"}, {"measure": "Change From Baseline in the Forced Expiratory Volume in 1 Second Standardized (With Respect to Time) Area Under the Curve (AUC) From 0 to 48 Hours (FEV1 AUC 0-48h) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC 0-48 hours) of FEV1 measurements taken at pre-dose to 48 hours post-dose was calculated based on the trapezoidal rule and was adjusted for the area per time unit by using the scheduled time of measurements for FEV1. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "timeFrame": "Baseline, 0 to 48 hours post dose week 2"}], "secondaryOutcomes": [{"measure": "Change From Baseline in the Forced Expiratory Volume in 1 Second Standardized (With Respect to Time) Area Under the Curve (AUC) From 0 to 12 Hours (FEV1 AUC 0-12h) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC 0-12 hours) of FEV1 measurements taken at pre-dose to 12 hours post-dose was calculated based on the trapezoidal rule and was adjusted for the area per time unit by using the scheduled time of measurements for FEV1. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "timeFrame": "Baseline, 0 to 12 hours post dose week 2"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a diagnosis of asthma and:\n* Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening\n* FEV1 \u226550% and \u226490% of predicted normal at screening\n* An increase of \u226512% and \u2265200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling a total dose of albuterol/salbutamol of 360/400 MDI\n\nExclusion Criteria:\n\n* Smoking history of \u2265 10 years\n* Patients with a diagnosis of COPD\n* Patients who have been previously intubated for a severe asthma exacerbation/ attack\n* Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening\n* Patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to screening\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with seasonal allergy whose asthma is likely to deteriorate during the study period\n* Patients with Type I or uncontrolled Type II diabetes mellitus\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Anniston", "state": "Alabama", "zip": "36207", "country": "United States", "geoPoint": {"lat": 33.65983, "lon": -85.83163}}, {"facility": "Novartis Investigative Site", "city": "Cypress", "state": "California", "zip": "90630", "country": "United States", "geoPoint": {"lat": 33.81696, "lon": -118.03729}}, {"facility": "Novartis Investigative Site", "city": "Fresno", "state": "California", "zip": "93726", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Novartis Investigative Site", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Novartis Investigative Site", "city": "Miami", "state": "Florida", "zip": "33167", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigative Site", "city": "Miami", "state": "Florida", "zip": "33175", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigative Site", "city": "Sarasota", "state": "Florida", "zip": "34233", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Novartis Investigative Site", "city": "Tampa", "state": "Florida", "zip": "33617", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Novartis Investigative Site", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Novartis Investigative Site", "city": "Lafayette", "state": "Louisiana", "zip": "70503", "country": "United States", "geoPoint": {"lat": 30.22409, "lon": -92.01984}}, {"facility": "Novartis Investigative Site", "city": "Las Vegas", "state": "Nevada", "zip": "89119", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "state": "New Jersey", "zip": "08009", "country": "United States", "geoPoint": {"lat": 39.79123, "lon": -74.92905}}, {"facility": "Novartis Investigative Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Novartis Investigator Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77070", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Plano", "state": "Texas", "zip": "75075", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Novartis Investigative Site", "city": "San Antonio", "state": "Texas", "zip": "78212", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Novartis Investigative Site", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Novartis Investigative Site", "city": "Tacoma", "state": "Washington", "zip": "98418", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Novartis Investigative Site", "city": "Paris", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigative Site", "city": "Rennes", "country": "France", "geoPoint": {"lat": 48.11198, "lon": -1.67429}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Amman", "country": "Jordan", "geoPoint": {"lat": 31.95522, "lon": 35.94503}}, {"facility": "Novartis Investigative Site", "city": "Irbid", "country": "Jordan", "geoPoint": {"lat": 32.55556, "lon": 35.85}}, {"facility": "Novartis Investigative Site", "city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novartis Investigative Site", "city": "Manchester", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Novartis Investigative Site", "city": "Merthyr Tydfil", "country": "United Kingdom", "geoPoint": {"lat": 51.74794, "lon": -3.37779}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study consisted of a 21 day screening period, a 14 day run-in period and a baseline assessment day prior to the 16 day treatment period. 1 participant randomized to 75 ug Indacaterol and 1 participant randomized to Placebo did not receive study drug and were not included in the Safety set milestone.", "groups": [{"id": "FG000", "title": "Indacaterol 37.5 \u00b5g (Twice a Day)", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG001", "title": "Indacaterol 75 \u00b5g (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG002", "title": "Indacaterol 150 \u00b5g (Every Other Day)", "description": "Indacaterol 150 \u00b5g every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 \u00b5g inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "FG003", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized participants.", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "48"}, {"groupId": "FG002", "numSubjects": "48"}, {"groupId": "FG003", "numSubjects": "47"}]}, {"type": "PD & Safety Sets: Received Study Drug", "achievements": [{"groupId": "FG000", "comment": "PD=Pharmacodynamic", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "47"}, {"groupId": "FG002", "numSubjects": "48"}, {"groupId": "FG003", "numSubjects": "46"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}, {"groupId": "FG001", "numSubjects": "46"}, {"groupId": "FG002", "numSubjects": "42"}, {"groupId": "FG003", "numSubjects": "41"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Indacaterol 37.5 \u00b5g (Twice a Day)", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG001", "title": "Indacaterol 75 \u00b5g (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG002", "title": "Indacaterol 150 \u00b5g (Every Other Day)", "description": "Indacaterol 150 \u00b5g every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 \u00b5g inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG003", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "48"}, {"groupId": "BG003", "value": "46"}, {"groupId": "BG004", "value": "189"}]}], "measures": [{"title": "Age Continuous", "description": "Baseline measures used the Safety Set that included all participants who received at least one dose of study drug.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37.4", "spread": "11.0"}, {"groupId": "BG001", "value": "41.1", "spread": "14.7"}, {"groupId": "BG002", "value": "42.0", "spread": "12.2"}, {"groupId": "BG003", "value": "40.8", "spread": "12.7"}, {"groupId": "BG004", "value": "40.3", "spread": "12.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "18"}, {"groupId": "BG004", "value": "79"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "32"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "110"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Trough FEV1 values were calculated as the mean of the 23.17 hours and 23.75 hours post morning dose FEV1 measurements. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "populationDescription": "Pharmacodynamic (PD) Analysis Set included all randomized participants who received at least one dose of study drug and who had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline to week 2", "groups": [{"id": "OG000", "title": "Indacaterol 37.5 \u00b5g (Twice a Day)", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 75 \u00b5g (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Indacaterol 150 \u00b5g (Every Other Day)", "description": "Indacaterol 150 \u00b5g every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 \u00b5g inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG003", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.156", "lowerLimit": "0.083", "upperLimit": "0.228"}, {"groupId": "OG001", "value": "0.197", "lowerLimit": "0.125", "upperLimit": "0.269"}, {"groupId": "OG002", "value": "0.199", "lowerLimit": "0.125", "upperLimit": "0.272"}, {"groupId": "OG003", "value": "-0.005", "lowerLimit": "-0.080", "upperLimit": "0.071"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Forced Expiratory Volume in 1 Second Standardized (With Respect to Time) Area Under the Curve (AUC) From 0 to 24 Hours Post Dose (FEV1 AUC 0-24h) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC 0-24 hours) of FEV1 measurements taken at pre-dose to 24 hours post-dose was calculated based on the trapezoidal rule and was adjusted for the area per time unit using the scheduled time of measurements for FEV1. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "populationDescription": "Pharmacodynamic (PD) Analysis Set included all randomized participants who received at least one dose of study drug and who had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline, 0-24 hours post dose week 2", "groups": [{"id": "OG000", "title": "Indacaterol 37.5 \u00b5g (Twice a Day)", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 75 \u00b5g (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) such as salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.196", "lowerLimit": "0.127", "upperLimit": "0.266"}, {"groupId": "OG001", "value": "0.198", "lowerLimit": "0.127", "upperLimit": "0.269"}, {"groupId": "OG002", "value": "0.030", "lowerLimit": "-0.044", "upperLimit": "0.103"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in the Forced Expiratory Volume in 1 Second Standardized (With Respect to Time) Area Under the Curve (AUC) From 0 to 48 Hours (FEV1 AUC 0-48h) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC 0-48 hours) of FEV1 measurements taken at pre-dose to 48 hours post-dose was calculated based on the trapezoidal rule and was adjusted for the area per time unit by using the scheduled time of measurements for FEV1. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "populationDescription": "Pharmacodynamic (PD) Analysis Set included all randomized participants who received at least one dose of study drug and who had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline, 0 to 48 hours post dose week 2", "groups": [{"id": "OG000", "title": "Indacaterol 75 \u00b5g (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 150 \u00b5g (Every Other Day)", "description": "Indacaterol 150 \u00b5g every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 \u00b5g inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) such as salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.218", "lowerLimit": "0.148", "upperLimit": "0.288"}, {"groupId": "OG001", "value": "0.198", "lowerLimit": "0.135", "upperLimit": "0.260"}, {"groupId": "OG002", "value": "0.059", "lowerLimit": "-0.012", "upperLimit": "0.129"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Forced Expiratory Volume in 1 Second Standardized (With Respect to Time) Area Under the Curve (AUC) From 0 to 12 Hours (FEV1 AUC 0-12h) After Two Weeks of Treatment", "description": "Spirometry was conducted according to internationally accepted standards. Standardized area under the curve (AUC 0-12 hours) of FEV1 measurements taken at pre-dose to 12 hours post-dose was calculated based on the trapezoidal rule and was adjusted for the area per time unit by using the scheduled time of measurements for FEV1. Analysis of covariance model was used with baseline FEV1 as a continuous covariate.", "populationDescription": "Pharmacodynamic (PD) Analysis Set included all randomized participants who received at least one dose of study drug and who had evaluable PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Liters", "timeFrame": "Baseline, 0 to 12 hours post dose week 2", "groups": [{"id": "OG000", "title": "Indacaterol 37.5 \u00b5g (Twice a Day)", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG001", "title": "Indacaterol 75 \u00b5g (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."}, {"id": "OG002", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) such as salbutamol/albuterol was available for rescue use throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.245", "lowerLimit": "0.170", "upperLimit": "0.319"}, {"groupId": "OG001", "value": "0.243", "lowerLimit": "0.163", "upperLimit": "0.317"}, {"groupId": "OG002", "value": "0.059", "lowerLimit": "-0.018", "upperLimit": "0.137"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "4", "description": "Safety population.", "eventGroups": [{"id": "EG000", "title": "Indacaterol 37.5 ug (Twice a Day)", "description": "Indacaterol 37.5 \u00b5g twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 48, "otherNumAffected": 7, "otherNumAtRisk": 48}, {"id": "EG001", "title": "Indacaterol 75 ug (Once a Day)", "description": "Indacaterol 75 \u00b5g once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 47, "otherNumAffected": 8, "otherNumAtRisk": 47}, {"id": "EG002", "title": "Indacaterol 150 ug (Every Other Day)", "description": "Indacaterol 150 \u00b5g every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 \u00b5g inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 1, "seriousNumAtRisk": 48, "otherNumAffected": 11, "otherNumAtRisk": 48}, {"id": "EG003", "title": "Placebo", "description": "Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days. All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) \u03b22-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study.", "seriousNumAffected": 0, "seriousNumAtRisk": 46, "otherNumAffected": 8, "otherNumAtRisk": 46}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 46}]}], "otherEvents": [{"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 46}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 46}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 46}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 6, "numAtRisk": 46}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 46}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M245808", "name": "Maleic acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}